Dr. John Dick

  • Co-Investigator, PMH (Cancer Evolution)

Dr. John Dick’s world-renowned research program centres on the theme that genetic and non-genetic determinants of tumour heterogeneity are linked through stemness. This is based on his research that identified a shared genetic signature between hematopoietic stem cells and leukemic stem cells that predicts survival across a wide spectrum of leukemias. Dr. Dick is extending these findings by developing a map of the determinants of stemness. This will enable genetic, epigenetic and proteomic studies that will enhance the robustness of prognostic cancer stem cell signatures and identify novel therapeutic targets that control stemness.

He will also continue his research describing the functional and genomic clonal heterogeneity in leukemia. Through characterizing this diversity among leukemic populations, Dr. Dick will be able to examine the functional properties and therapeutic responses of individual subclones. These studies in leukemia are guided by parallel studies his team has undertaken to define the landscape of normal human hematopoietic development. This combined program will lead to deep insights into the stemness programs that lie at the heart of stem cell functioning. Ultimately his research program will lead to new clinically meaningful biomarker tests and novel therapeutic agents that target tumour stem cells.

Current Affiliations
  • Co-Investigator, Princess Margaret Hospital, The Detection of Early Cancer Evolution
  • Co-leader, Acute Leukemia TRI, OICR
  • Canada Research Chair in Stem Cell Biology, Senior Scientist, Princess Margaret Cancer Centre, University Health Network
  • Investigator, McEwen Centre for Regenerative Medicine, University Health Network
  • Professor, Department of Molecular and Medical Genetics, University of Toronto